Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISTAHIT: High-Dose vs Standard Imatinib in Pretreated CML
NCT00327262Phase 3Unknown
- Sponsor
- Central European Leukemia Study Group
- Start
- Jan 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of imatinib in Chronic Myeloid Leukemia (CML), sponsored by Central European Leukemia Study Group. Status: unknown.
02
Drugs
03
Conditions
Chronic Myeloid Leukemia (CML)
Beyond the preview
Go deeper on NCT00327262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00327262.